Trial Profile
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial With Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 18 May 2022 Results published in the Ophthalmology and Therapy
- 10 Jul 2019 Status changed from recruiting to completed.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.